by Raynovich Rod | Apr 11, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in...
by Raynovich Rod | Apr 9, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 4/10 Abrupt Sell-Off –Failure to Confirm Bottom NASDAQ down 71 pts 1.7% All of yesterdays’ gains wiped out and we are back to January levels. Raise cash levels to 30% on life science portfolios. Many high fliers and core holdings are selling off...
by Raynovich Rod | Apr 8, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
NASDAQ Up 0.37% to 4133 Green screen alert with large cap biotechs. Time to cover hedges. Alexion (ALXN) up 2.23% Biogen (BIIB) Up 2.4% Celgene (CELG) up 3.61% Clovis Oncology (CLVS) up 2.85% Gilead (GILD) up 1.35% IBB up 1.96% Regeneron (REGN) up 3.99% Key Trends To...
by Raynovich Rod | Apr 1, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Biopharmaceutical Portfolio 3/31/14 Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the...
by Raynovich Rod | Mar 18, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer...
by Raynovich Rod | Mar 17, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Life Science ETF's and Mutual Funds
XBI Outperforms FBIOX YTD Many biotech stocks sold off today despite a strong market on weak volume as industrials and tech were up about 1.4%. Watch the ETFs compared to Fidelity FBIOX because the sector is more volatile this month. Here is a chart comparing three...
by Raynovich Rod | Mar 13, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
March 17 Update -GREEN DAY with Geopolitical risk on back burner As of 11.38a EDT Industrials lead up 1%, healthcare up 0.8%, IBB up 1.33% Biopharmaceuticals stocks were strong with Rayno large cap picks: Alexion (ALXN $117) up 1.45%, Amgen (AMGN $125) up 1.9%,...
by Raynovich Rod | Mar 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Mini-Rally in Life Science Stocks— Update 10p PDT Biotech stocks recovered off their am lows today with major ETFs (FBT,IBB,XBI ($161.45) up about 0.3% and within 5% of highs. Over the past week or so biopharma stocks have been weak with a “topping”...
by Raynovich Rod | Feb 27, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Clinical Diagnostics and Tools
Rayno Life Science Movers -Diagnostics Review Next Week Despite some choppiness in biotech trading this week many of our stocks did well. I won’t go into some of the unusual volatility in other small and mid-caps lately but that is part of the reason for my...
by Raynovich Rod | Feb 25, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech May Be A Bubble-But What to Do? The blogosphere is trying to temper bullish sentiment with a lot of “bubble “talk even though the cable channels are still pumping biotech. If you have been around biotech for 25 years especially during the last...
